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Abstract
Introduction: Dysferlin loss-of-function mutations cause muscular dystrophy, accompa-
nied by impaired membrane repair and muscle weakness. Growth promoting strategies
including insulin-like growth factor 1 (IGF-1) could provide benefit but may cause
strength loss or be ineffective. The objective of this study was to determine whether
locally increased IGF-1 promotes functional muscle hypertrophy in dysferlin-null
(Dysf−/−) mice.
Methods: Muscle-specific transgenic expression and postnatal viral delivery of Igf1
were used in Dysf−/− and control mice. Increased IGF-1 levels were confirmed by
enzyme-linked immunosorbent assay. Testing for skeletal muscle mass and function
was performed in male and female mice.
Results: Muscle hypertrophy occurred in response to increased IGF-1 in mice with
and without dysferlin. Male mice showed a more robust response compared with
females. Increased IGF-1 did not cause loss of force per cross-sectional area in
Dysf−/− muscles.
Discussion:We conclude that increased local IGF-1 promotes functional hypertrophy
when dysferlin is absent and reestablishes IGF-1 as a potential therapeutic for
dysferlinopathies.
K E YWORD S
dysferlin, insulin-like growth factor 1, Miyoshi myopathy, muscle hypertrophy, skeletal muscle
function
1 | INTRODUCTION
Loss-of-function mutations in the dysferlin gene (Dysf ) in humans results
in a spectrum of muscular dystrophies known as dysferlinopathies.1
The dysferlinopathies manifest as distal anterior compartment
myopathy,2 limb-girdle muscular dystrophy type 2B (LGMD2B),3 and
Abbreviations: Akt, protein kinase b; ANOVA, analysis of variance; Dysf, dysferlin gene;
Dysf−/−, dysferlin null; Dysf−/−:mIgf+/+, mice homozygous for the loss of dysferlin and
transgenic expression of Igf1; Dysf−/−:mIgf−/−, mice homozygous for the loss of dysferlin with
no transgenic expression of Igf1; Dysf+/+:mIgf+/+, mice with wildtype levels of dysferlin and
transgenic expression of Igf1; Dysf+/+:mIgf−/−, mice wildtype for both genes; EDL, extensor
digitorum longus; ELISA, enzyme-linked immunosorbent assay; IGF-1, insulin-like growth
factor 1; LGMD2B, limb-girdle muscular dystrophy type 2B; MHC, myosin heavy chain;
mIgf+/+, muscle-specific IGF-1 transgene; scAAV, self-complementing adenoassociated virus;
TA, tibialis anterior.
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Miyoshi myopathy.4 The primary pathological consequences include
defective membrane repair and intracellular vesicle accumulation.5 The
clinical problem associated with dysferlin loss is progressive muscle
weakening, which begins in proximal muscles in LGMD2B and in distal
muscles in Miyoshi myopathy.6
Dysferlin is a 230-kDa type II transmembrane protein7 localized at
the sarcolemma of mature skeletal muscle but also at transverse tubules
in developing myotubes.8 Dysferlin contains seven C2 domains9 and a
transmembrane domain.10 The first C2 domain (C2A) can bind several
phospholipids in a calcium-dependent manner.11 There is a plethora of
evidence that implicates dysferlin as an essential regulator of vesicle
fusion at the sarcolemma and an important player in muscle membrane
repair.12 However, dysferlin is not limited to sarcolemma repair but is
also involved in muscle regeneration,13 focal adhesion formation,14
adenosine triphosphate-dependent intercellular signaling,15 and insulin-
like growth factor 1 (IGF-1) receptor recycling.16
There is no effective treatment for increasing muscle strength or for
preventing further muscle damage in these diseases. A potential treat-
ment for dysferlinopathies is the use of IGF-1. Insulin-like growth factor
1 is a circulating autocrine/paracrine factor that regulates many aspects
of muscle development, repair, and growth.17,18 Increasing IGF-1 in mus-
cle causes hypertrophy, enhances regeneration after injury, and can
improve many diseased muscle phenotypes and functions.19-26 However,
systemic delivery of recombinant IGF-1 was ineffective at promoting the
hypertrophic responses in dysferlin null (Dysf−/−) mice, and the failure
was ascribed to the lack of properly localized IGF-1 receptors.16
A second potential treatment for dysferlinopathies is myostatin inhi-
bition. As a negative regulator of muscle growth, a number of strategies
have been developed to block myostatin activity and boost muscle
mass. Indeed, transgenic expression of follistatin and delivery of a solu-
ble form of the myostatin receptor led to significant hypertrophy of
muscles in the Dysf−/−mouse27; however, this was accompanied by pro-
gressive deficits of muscle function due to acceleration of degeneration.
Because of the lack of efficacy for systemic IGF-1 delivery and the
risks of any progrowth strategy to potentially cause degeneration of
dysferlin-deficient muscles, the objective of this study was twofold.
First, we sought to determine whether local expression of IGF-1 could
overcome the limitations of systemic delivery and promote gains in mus-
cle mass in dysferlin-deficient mice. Second, we sought to determine
whether any increase in muscle mass was associated with loss of force
generating capacity.
2 | MATERIAL AND METHODS
2.1 | Animal studies
Animal studies were performed in accordance with and were
approved by the University of Pennsylvania animal care committee.
For transgenic studies, muscle-specific IGF-1 transgenic (mIgf+/+) male
mice28 that had been backcrossed to the C57BL/6 J strain were bred
with female Bla/J (JAX No. 012767). Male and female mice from the
F2 generation were used, and mice with the desired genotypes were
used for the experiments. These included mice homozygous for the
loss of dysferlin and transgenic expression of Igf1 (Dysf−/−:mIgf+/+),
mice homozygous for the loss of dysferlin with no transgenic expres-
sion of Igf1 (Dysf−/−:mIgf−/−), mice with wildtype levels of dysferlin
and transgenic expression of Igf1 (Dysf+/+:mIgf+/+), and mice wildtype
for both genes (Dysf+/+:mIgf−/−). Male and female mice 16 weeks of
age were used for analysis.
In postnatal viral delivery experiments, controls were male and
female dysferlin-deficient A/J mice (JAX No. 000646) and A/WySnJ
mice (JAX No. 006647), which is a commercially available inbred strain
that is a suitable control for A/J mice. A/J mice are referred to as
Dysf−/−, and A/WySnJ mice are referred to as Dysf+/+. Both Dysf−/−
lines bear an early ETn retrotransposon insertion in intron 4 of the
dysferlin gene, resulting in disruption of the dysferlin gene expression.
2.2 | Viral injections
Recombinant self-complementing adenoassociated virus (scAAV) sero-
type 2/8 vectors expressing the Igf1 cDNA of murine class I IGF-1A
under the control of the chicken β-actin promoter and cytomegalovirus
enhancer were generated by the Children's Hospital of Philadelphia
Vector Core, as previously described.29 Self-complementing ade-
noassociated virus was diluted with phosphate-buffered saline to
1 × 109 viral particles/μL, and 50 μL was injected into each of the ante-
rior and posterior compartments of one lower hind limb of anesthetized
3-week-old Dysf−/− and Dysf+/+ mice, targeting the tibialis anterior (TA),
extensor digitorum longus (EDL), and soleus muscles. The contralateral
F IGURE 1 Transgenic Igf1 expression increases skeletal muscle mass independent of dysferlin with no functional decrement. A,B,
Bodyweights of male (A) and female (B) mice show significant increases in male Dysf−/− and females of both mIgf1+/+ strains. C,D, TA muscle mass
in male mice increased ~30% in both mIgf1+/+ strains and ~20% in female mice. Only Dysf−/− mice displayed significant hypertrophy in EDL and
soleus. EDL muscle tetanic forces from male (E) and female (F) mice were significantly higher in Dysf−/−:mIgf+/+ mice compared with Dysf−/−:
mIgf−/− mice. EDL muscle-specific forces from male (G) and female (H) mice showed no significant differences among groups. Diaphragm-specific
forces from male mice (I) show significant reduction between Dysf+/+:mIgf−/− and Dysf−/− muscles of both mIgf1+/+ strains. Diaphragm-specific
forces in female mice (J) were not different across all strains. Data are mean ± SEM for males (Dysf+/+:mIgf−/−, n = 6–7; Dysf+/+:mIgf+/+, n = 4–9;
Dysf−/−:mIgf−/−, n = 4–7; Dysf−/−:mIgf+/+, n = 6–9) and females (Dysf+/+:mIgf−/−, n = 5–6; Dysf+/+:mIgf+/+, n = 4–6; Dysf−/−:mIgf−/−, n = 4–6;
Dysf−/−:mIgf+/+, n = 4–7). *P < .05; **P < .01, ***P < .001 for comparisons between mIgf1−/− and mIgf1+/+, two-way ANOVA with Tukey's
multiple-comparison test. ANOVA, analysis of variance; DP, diaphragm; Dysf−/−, dysferlin null; Dysf−/−:mIgf+/+, mice homozygous for the loss of
dysferlin and transgenic expression of Igf1; Dysf−/−:mIgf−/−, mice homozygous for the loss of dysferlin with no transgenic expression of Igf1;
Dysf+/+:mIgf+/+, mice with wildtype levels of dysferlin and transgenic expression of Igf1; Dysf+/+:mIgf−/−, mice wildtype for both genes; EDL,
extensor digitorum longus; IGF-1, insulin-like growth factor 1; mIgf+/+, muscle-specific IGF-1 transgene; TA, tibialis anterior [Color figure can be
viewed at wileyonlinelibrary.com]
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limb was used as control. After injection, mice were housed in the ani-
mal facility until time of analysis. They were humanely killed 1 week,
1 month, or 2 months after injection, and tissues were obtained for
functional, biochemical, and morphological analysis.
2.3 | Functional analysis of isolated muscles
Muscle function testing was performed in EDL, soleus, and diaphragm
muscles according to previously published protocols.28,29 Maximum iso-
metric tetanic forces were measured at fusion frequency and supra-
maximal stimulation. After completion of the mechanical procedures,
muscles were blotted, weighted, and rapidly frozen for subsequent
assays. Muscle-specific forces (N/cm2) were calculated by normalizing
the maximum muscle tension to the muscle cross-sectional area.
2.4 | Immunohistochemistry
Fiber type, size, and number analyses were performed in EDL and
soleus cryosections with anti-laminin (FB-082A; ThermoFisher Scien-
tific) and anti-myosin heavy chain IIA (Sc-71; Developmental Studies
Hybridoma Bank), as previously described.30 Stained sections were
visualized with a Leica DMR microscope. Fiber type and size quantita-
tion were performed in SMASH software.31
2.5 | Muscle IGF-1 content
Muscle IGF-1 levels were determined with the rat/mouse IGF-1
enzyme-linked immunosorbent assay (ELISA) kit (Cat. No. MG100; R&D
Systems) in accordance to the manufacturer's instructions and as
F IGURE 2 Transgenic Igf1 expression increases muscle mass due to increase in fiber size. Transverse sections of EDL muscles were
immunostained for laminin to determine fiber number and size. A,B, There was no difference in total fiber number among the strains examined.
Minimum Feret diameter distribution revealed a rightward shift in EDL muscles from Dysf+/+ (C,D) and to a lesser extent in Dysf−/− (E,F) mice.
Data are mean ± SEM for n = 3–8 for all groups. *P < .05 for comparisons between mIgf1−/− and mIgf1+/+, two-way ANOVA, followed by Tukey's
multiple-comparison test. ANOVA, analysis of variance; Dysf+/+, dysferlin; Dysf−/−, dysferlin null; Dysf−/−:mIgf+/+, mice homozygous for the loss of
dysferlin and transgenic expression of Igf1; Dysf−/−:mIgf−/−, mice homozygous for the loss of dysferlin with no transgenic expression of Igf1;
Dysf+/+:mIgf+/+, mice with wildtype levels of dysferlin and transgenic expression of Igf1; Dysf+/+:mIgf−/−, mice wildtype for both genes; EDL,
extensor digitorum longus; IGF-1, insulin-like growth factor 1; mIgf+/+, muscle-specific IGF-1 transgene; TA, tibialis anterior [Color figure can be
viewed at wileyonlinelibrary.com]
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previously described.32 Data are expressed as nanograms IGF-1 per gram
of tissue.
2.6 | Immunoblotting
Tissues that had been extracted for immunoblot analysis were snap-
frozen in liquid nitrogen and stored at −80C until further processing.
Tibialis anterior muscles were mechanically ground by mortar and pestle
in dry ice and homogenized in radioimmunoprecipitation assay buffer,
with the addition of phenylmethylsulfonyl fluoride, protease, and phos-
phatase inhibitors. Proteins were quantitated by Bradford assay, and
equal amounts were loaded in 12% precast acrylamide gels for sodium
dodecyl sulfate polyacrylamide gel electrophoresis and transferred to
polyvinylidene fluoride membrane. Primary antibodies for phospho–
protein kinase b (Akt; Ser473; cat. No. 9271; Cell Signaling Technology)
and total Akt (pan; 40D4; cat. No. 2920; Cell Signaling Technology) were
used to measure the changes in Akt phosphorylation, which was evalu-
ated in ImageJ.
2.7 | Statistical analysis
All data are presented as mean ± SEM. All analysis was performed in
Prism 8 (GraphPad Software). Student's t test was performed for com-
parison of two groups, and two-way analysis of variance (ANOVA)
was performed for comparison of three or more groups to determine
significance, followed by Tukey's multiple-comparisons post hoc test-
ing. P < .05 was considered significant.
3 | RESULTS
3.1 | Transgenic IGF-1 expression mediates
hypertrophy in the absence of dysferlin
Mice with transgenic expression of Igf1 were compared with age- and
sex-matched littermate controls in terms of body and muscle mass. In
male mice, there was a significant effect of increased IGF-1 and
absence of dysferlin on body weight according to two-way ANOVA,
with increased body weight evident in Dysf−/− mice according to post
F IGURE 3 Transgenic Igf1 expression increases IGF-1 content in both male and female muscles independent of strain. IGF-I content of TA muscles
was measured by ELISA in male (A) and female (B) mice. Muscles from mIgf1+/+ mice had IGF-1 levels greater than 10-fold higher compared with strain
and sex-matchedmIgf1−/− mice. Mean ± SEM for n = 4–9 for all groups. C,D, Correlations between IGF-1 content and mass for TA muscles are shown
for male and female mice. R2 calculated for low and high IGF-1 content separately. Analysis by two-way ANOVA, followed by Tukey's multiple
comparison test. *P < .05, **P < .01, ****P < .0001 for comparisons between mIgf1−/− and mIgf1+/+; ††P < .01 for comparison between Dysf−/− and
Dysf+/+. ANOVA, analysis of variance; Dysf+/+, dysferlin; Dysf−/−, dysferlin null; Dysf−/−:mIgf+/+, mice homozygous for the loss of dysferlin and transgenic
expression of Igf1; Dysf−/−:mIgf−/−, mice homozygous for the loss of dysferlin with no transgenic expression of Igf1; Dysf+/+:mIgf+/+, mice with wildtype
levels of dysferlin and transgenic expression of Igf1; Dysf+/+:mIgf−/−, mice wildtype for both genes; ELISA, enzyme-linked immunosorbent assay; IGF-1,
insulin-like growth factor 1; mIgf+/+, muscle-specific IGF-1 transgene; TA, tibialis anterior [Color figure can be viewed at wileyonlinelibrary.com]
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hoc analysis (Figure 1A). In contrast, female mice displayed significant
responses of body weight to increased IGF-1 in both strains
(Figure 1B). Male mice exhibited hypertrophy in TA muscles with
transgenic expression of Igf1 regardless of strain, and EDL and soleus
muscles were also larger in Dysf−/−:mIgf1+/+ mice (Figure 1C). Female
mice displayed a less robust hypertrophic response to IGF-1, with sig-
nificantly increased mass in only fast twitch muscles (EDL, TA) of
Dysf−/− mice (Figure 1D), which was similar to what has been reported
in previous studies.28 Thus, the effects of IGF-1 on muscle do not
require dysferlin, and, in fact, there is an enhanced hypertrophic effect
in the absence of dysferlin.
Isolated muscle function testing was performed on the EDL and
diaphragm to determine whether changes in muscle mass in mIgf1+/+
mice were accompanied by changes in the force-generating capacity
of the muscles. Isometric tetanic force significantly increased in EDL
muscles of male and female Dysf−/− mice (Figure 1E,F). No changes in
the specific force in response to high IGF-1 were observed in EDL
muscles (Figure 1G,H), indicating that total tetanic force increased in
proportion to mass. For diaphragm muscles (Figure 1I,J), there was sig-
nificance for both IGF-I and strain by two-way ANOVA. In post hoc
comparisons, the diaphragm from the male Dysf−/− mice displayed an
~30% deficit in force compared with muscles from Dysf+/+ mice, which
was less pronounced than previous findings in the A/J strain of mice
in terms of diaphragm function.29 Increased IGF-1 combined with
dysferlin loss did not rescue the specific force deficit compared with
Dysf−/−:mIgf1−/− mice. No deficits in diaphragm function were appar-
ent in the female mice regardless of strain.
To investigate whether the observed gain of muscle mass was due
to increased muscle fiber numbers or fiber size, EDL muscle morphol-
ogy was analyzed by immunostaining with anti-laminin. Muscle fiber
analysis revealed that there were no differences in fiber number
across the genetic conditions (Figure 2A,B). Instead, minimum Feret
diameter increased in Dysf+/+ mice harboring the mIgf1 transgene,
with a rightward shift in the fiber size distribution (Figure 2C,D). In
Dysf−/− mice, the shift was minimal and was apparent only in the pres-
ence of large muscle fibers in males (Figure 2E,F). A small cohort of
soleus muscles were similarly evaluated. Transgenic expression of
IGF-1 did not alter fiber type, which ranged from 52% to 56.6% myo-
sin heavy chain (MHC) IIA fibers independent of strain or sex. Because
Igf1 expression in this transgenic mouse is regulated by the myosin
light chain 1/3 promoter/enhancer, the levels of IGF-1 production in
the soleus is lower than MHC IIB/X containing fibers, resulting in min-
imal hypertrophy, as has been previously shown.28
To determine whether differences in the extent of response to
IGF-1 were dependent on the IGF-1 content within the muscles, we
measured IGF-1 levels in TA muscles by ELISA for male and female
mice in all strains. Insulin-like growth factor 1 levels were more than
10-fold higher in all mice harboring the mIgf1 transgene (Figure 3A,B).
In mIgf1+/+ males, the level of IGF-1 was higher in muscles of Dysf−/−
mice than in muscles of Dysf+/+ mice. To gain a better understanding
of the relationship between IGF-1 levels and muscle mass, correla-
tions between IGF-1 content and mass for TA muscles were examined
in each sex. We found that, instead of a uniform linear relationship,
there were two distinct populations of samples. With IGF-1 levels
below 50 ng/g muscle, R2 = 0.138 (males) and R2 = 0.411 (females)
were observed. When IGF-1 was above 50 ng/g muscle, there was no
relationship, with R2 values approaching zero (Figure 3C,D). These
results indicate that there is saturation of the effect of IGF-1 on mus-
cle mass when it exceeds three times the endogenous levels of this
growth factor.
3.2 | Postnatal increase in IGF-1 mediates
hypertrophy in the absence of dysferlin
Transgenic expression of IGF-1 provides a growth stimulus initiated
before birth. To determine whether postnatal modulation of IGF-1
could also drive hypertrophy in the absence of dysferlin, we used viral
mediated gene transfer into muscles of young Dysf+/+ and Dysf−/−
mice with scAAV vectors encoding IGF-1A. At 1 week postinjection,
IGF-1 content was ~10-fold higher in the injected muscles compared
with contralateral control muscles in both genotypes (Figure 4A).
There was no significant difference in basal IGF-1 or postinjected IGF-1
F IGURE 4 Viral delivery of IGF-1 leads to increased signaling of
IGF-1 pathways. A, IGF-1 content was significantly higher after viral
delivery in TA muscles from Dysf+/+ and Dysf−/− mice (n = 3 pairs for
each genotype). There was no significant difference in basal IGF-1 or
in postinjected IGF-1 between mouse strains. B, Immunoblot of P-Akt
and T-Akt in TA muscle lysates with and without AAV–IGF-1
injection. C, P-Akt levels were increased in the scAAV–IGF-1A
injected muscles (+AAV) compared with contralateral control muscles
(−AAV) from both Dysf+/+ and Dysf−/− mice (n = 3 pairs for each
genotype). *P < .05 between injected and uninjected muscles, two-
tailed paired Student's t test. Dysf+/+, dysferlin; Dysf−/−, dysferlin null;
IGF-1, insulin-like growth factor 1; P-Akt, phospho–protein kinase b;
scAAV, self-complementing adenoassociated virus; TA, tibialis
anterior; T-Akt total-protein kinase b [Color figure can be viewed at
wileyonlinelibrary.com]
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between mouse strains. We examined phosphorylation of Akt as a
downstream index of IGF-1 receptor activation. Phospho-Akt increased
in the scAAV–IGF-1A-injected muscles compared with noninjected con-
trol muscles from both Dysf+/+ and Dysf−/− mice (Figure 4B,C).
To determine the effect of increased IGF-1 production on muscle
mass, limb muscles were dissected from male and female animals
1 month after adenoassociated virus (AAV) injection. In all mice, the
EDL muscles exhibited an ~15% increase in muscle mass in both
Dysf+/+ and Dysf−/− mice after viral injection (Figure 5A). This hyper-
trophic response was accompanied by a commensurate increase in
isometric tetanic force, resulting in similar specific forces in both
strains (Figure 5B,C). We extended measurements out to 2 months
postinjection, and similar effects on EDL mass and force production
were observed (Figure 5D-F). Thus, in fast skeletal muscles, postnatal
increases in IGF-1 mediate functional hypertrophy regardless of the
presence or absence of dysferlin.
In contrast to EDL muscles, soleus muscles were less responsive
to increased IGF-1. Specifically, there was a modest but significant
mass increase in soleus muscles from Dysf+/+ but not Dysf−/− mice
(Figure 6A). Isometric tetanic force displayed similar changes in that
only soleus muscles from Dysf+/+ mice had a 3% to 35% increase in
response to increased IGF-1 (Figure 6B). Evaluation of soleus muscle
at 2 months post–viral injection exhibited significant hypertrophy in
both strains (Figure 6D,E), with progressive increases in mass and
tetanic force compared with that observed at 1 month postinjection.
At both 1 and 2 months post–viral delivery, specific force production
by soleus muscles did not differ between treated and untreated limbs
(Figure 6C,F), reflecting an increase in force proportional to the
increases in mass. Thus, there is a hypertrophic response to increased
IGF-1 in the presence and absence of dysferlin, without negatively
affecting muscle functional properties.
4 | DISCUSSION
We found that boosting muscle IGF-1 in dysferlin-deficient mice through
transgenic overexpression and postnatal viral delivery led to increased
muscle mass without a decrement in force production. Thus IGF-1
should be considered as a potential therapeutic for LGMD2B/Miyoshi
myopathy.
Our previous evaluation of muscle function used dysferlin-
deficient A/J mice and the strain matched control A/WySnJ, in which
the mouse diaphragm displayed significant functional deficits in young
adult mice.29 However, few, if any, other mouse models of neuromus-
cular disease were on this background strain, making it difficult to
compare loss of dysferlin to other diseases without considering the
F IGURE 5 Functional hypertrophy by viral delivery of IGF-1 in EDL muscles occurs in Dysf+/+ and Dysf−/− mice. At 1 month postinjection,
EDL muscles exhibited a 10%–15% increase in mass (A) and a similar increase in tetanic force (B) in treated limbs in both Dysf+/+ and Dysf−/−
mice. Specific force (C) did not differ between treated and untreated limbs. At 2 months postinjection, there was a 17%–22% increase in EDL
muscle mass (D) in injected limbs, with tetanic force increasing 8%–40% (E). Similarly to the 1-month timepoint, specific force (F) was not
different between treated and untreated limbs. Muscles obtained from n = 6–8 mice per strain and timepoint. Male and female mice were
combined for analysis. Values are depicted as individual data points, with lines connecting the untreated and treated muscles from the same
mouse. **P < .01, ***P < .001 between injected and uninjected muscles, two-tailed paired Student's t test. AAV, adenoassociated virus;
Dysf+/+, dysferlin; Dysf−/−, dysferlin null; EDL, extensor digitorum longus; IGF-1, insulin-like growth factor 1, ns, not significant
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potential for strain-dependent genetic modifiers.33 With the develop-
ment of a dysferlin-deficient mouse on the C57Bl/6 background,34
more closely matched comparisons were possible, although it was
unclear whether the same pathological phenotypes would be retained.
Thus, for our transgenic crosses, it provided an opportunity to exam-
ine functional outcome measures of dysferlin loss on the C57Bl/6
background. The male Dysf−/− mice exhibited a 30% decrease in spe-
cific force only in the diaphragms, with no evidence of decreased spe-
cific forces in other muscle groups due to the absence of dysferlin.
Our previous findings in A/J mice, in which there were deficits of
~50% in specific force in the A/J diaphragm,29 suggest that the
physiological phenotype is altered in the C57Bl/6 strain. Previous
researchers have also compared disease severity with respect to
dysferlin mutation and background strain and found that the A/J
mouse C57Bl/6 background displayed highly variable recovery from
strain injury in contrast to three other mouse lines lacking dysferlin.35
These findings suggest that background strain may affect the patho-
genesis associated with the absence of dysferlin, as with other disease
models. Whether a single mouse strain can capture the essence of dis-
ease progression in humans is an open question, but our observations,
among others suggest that genetic modifiers are likely contributing to
variability in pathology of dysferlinopathies. The effects of IGF-1
appear to be independent of background strain, which suggests that a
therapeutic strategy including a boost of IGF-1 may be generally
effective in this disease.
We were struck by the differential response to transgenic expres-
sion of IGF-1 in male and female mice. Male mice displayed clear mus-
cle hypertrophy regardless of the presence of dysferlin in the TA
muscles, similarly to what has been reported in previous studies in
which this approach was used to boost muscle IGF-1 content in models
of disease,24,36,37 yet only in Dysf−/− mice was this accompanied by
increased body weight. In contrast, female mIgf+/+ mice exhibited
increased body weight in the presence and absence of dysferlin, but
muscle hypertrophy was not as extensive and was evident only in the
absence of dysferlin. Multiple issues arise with this observation. First, it
is clear that both males and females respond to high levels of IGF-I in
skeletal muscle, but female mice have a blunted hypertrophic response.
Second, a more speculative point is that, because increased muscle
mass combined with a lack of changed body weight in the male Dysf+/+:
mIgf+/+ mice occurs, it reflects findings in previous studies in which
modulating muscle IGF-1 led to sex-specific alterations locally in muscle
and globally in fat content.30,38-41 Thus, it is essential to evaluate male
and female mice separately for global IGF-1 dependent changes in
muscle mass.
F IGURE 6 Functional hypertrophy by viral delivery of IGF-1 on soleus muscles is blunted and delayed in Dysf−/− mice. At 1 month
postinjection, treated soleus muscles exhibited a 10%–15% increase in mass in Dysf+/+ mice but no significant increase in Dysf−/− mice (A).
Tetanic force was significantly increased in the treated soleus muscles only from Dysf+/+ mice (B). Specific force (C) did not differ between treated
and untreated limbs in both strains. At 2 months postinjection, treated soleus muscles from both strains showed significant increases in mass (D),
and only Dysf+/+mice had significant increases in tetanic force (E). Similarly to the 1-month timepoint, specific force (F) was not different between
treated and untreated limbs. Muscles obtained from n = 6–8 mice per strain and timepoint. Male and female mice were combined for analysis.
Values are depicted as individual data points, with lines connecting the untreated and treated muscles from the same mouse. *P < .05, **P < .01,
***P < .001 between injected and uninjected muscles, two-tailed paired Student's t test. AAV, adenoassociated virus; Dysf+/+, dysferlin; Dysf−/−,
dysferlin null; ns, not significant
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Complementary to lifetime exposure to IGF-1, postnatal viral deliv-
ery caused similar hypertrophy in male and female mice. However, the
soleus muscles in the Dysf−/− mice were delayed in responding to IGF-1;
hypertrophy was evident only 2 months after viral delivery. This sug-
gests that there is a fiber type specificity in the role that dysferlin plays
in mediating hypertrophy by IGF-1. In our previous study, we examined
the dysferlin levels in several skeletal muscles, including the soleus.29
The soleus did not have a different dysferlin level compared with the TA
or the EDL, which indicates that dysferlin content is independent of fiber
type, and this cannot explain the delayed response to increased IGF-1.
However, similarly to the negative findings after infusion of recombinant
IGF-1 into dysferlin-deficient animals,16 it provides evidence that there
is a blunted response to increased IGF-1. The remedy for the lack of
hypertrophy appears to be time because 1 month of treatment was not
sufficient for recombinant IGF-1 treatment or viral IGF-1 injection. How-
ever, 2 months after viral delivery and at 4 months of age with lifetime
exposure to IGF-1, there are significant increases in muscle mass. In
addition, the high levels of IGF-1 within the muscle are also a likely
advantage compared with the delivery of IGF-1 through the circulation.
The strategy to inhibit the myostatin pathway resulted in signifi-
cant hypertrophy27 but came at the expense of diminished func-
tional capacity. Analysis of EDL muscle function at 16 weeks of age
revealed a 30% decrease in specific force in dysferlin-deficient male
mice with transgenic expression of follistatin. Hence, we sought to
evaluate function in the EDL muscles at the same age. We observed
that mass and force production increased in tandem, resulting in no
differences in specific force and providing evidence that the IGF-1
and myostatin pathways are not driving a similar degenerative
response.
From the context of a therapeutic strategy, it is important to
determine an effective “dose” of IGF-1 for boosting muscle mass
without off-target effects. In our hands, more is not better because
IGF-1 levels five- to 25-fold above normal caused the same extent of
hypertrophy, indicating that there is a plateau for efficacy. In contrast,
systemic delivery of 2 mg/kg recombinant IGF-1, which is approxi-
mately 25-fold higher than the normal circulating levels, can drive
hypertrophy only in the presence of dysferlin,16 suggesting that sup-
raphysiologic levels are required to surpass the limitations of IGF-1
signaling in this disease when delivered through the circulation. From
a safety standpoint, delivery of such high levels through the blood-
stream is not clinically tenable, but, if an effective dose can be
achieved locally, then the safety concerns may be reduced. There is
no established method for boosting IGF-1 levels specifically in skeletal
muscle other than with AAV. This could be combined with restoring
dysferlin, similarly to the dystrophin replacement strategy demon-
strated in mouse models for Duchenne muscular dystrophy,42 provid-
ing both correction of the genetic defect and an enhancement of
functional hypertrophy.
In summary, we evaluated the therapeutic potential of IGF-1 for boo-
sting functional muscle mass in the absence of dysferlin. We observed
increased muscle mass and commensurate increases in force generation,
providing evidence that the IGF-1 pathway is sufficiently intact to medi-
ate functional hypertrophy. Going forward, we encourage our colleagues
to reconsider growth promoting strategies for LGMD2B and Miyoshi
myopathy patients.
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